BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

555 related articles for article (PubMed ID: 24133660)

  • 1. Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis.
    Koo SH
    Clin Mol Hepatol; 2013 Sep; 19(3):210-5. PubMed ID: 24133660
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Shi Y; Pizzini J; Wang H; Das F; Abdul Azees PA; Ghosh Choudhury G; Barnes JL; Zang M; Weintraub ST; Yeh CK; Katz MS; Kamat A
    Am J Physiol Endocrinol Metab; 2021 Jul; 321(1):E90-E104. PubMed ID: 34029162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acyl-Coenzyme A Thioesterase 9 Traffics Mitochondrial Short-Chain Fatty Acids Toward De Novo Lipogenesis and Glucose Production in the Liver.
    Steensels S; Qiao J; Zhang Y; Maner-Smith KM; Kika N; Holman CD; Corey KE; Bracken WC; Ortlund EA; Ersoy BA
    Hepatology; 2020 Sep; 72(3):857-872. PubMed ID: 32498134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fructose as a key player in the development of fatty liver disease.
    Basaranoglu M; Basaranoglu G; Sabuncu T; Sentürk H
    World J Gastroenterol; 2013 Feb; 19(8):1166-72. PubMed ID: 23482247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease.
    Kawano Y; Cohen DE
    J Gastroenterol; 2013 Apr; 48(4):434-41. PubMed ID: 23397118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
    Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
    Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of hepatic steatosis by dietary fatty acids.
    Ferramosca A; Zara V
    World J Gastroenterol; 2014 Feb; 20(7):1746-55. PubMed ID: 24587652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver sympathetic denervation reverses obesity-induced hepatic steatosis.
    Hurr C; Simonyan H; Morgan DA; Rahmouni K; Young CN
    J Physiol; 2019 Sep; 597(17):4565-4580. PubMed ID: 31278754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-Alcoholic Fatty Liver Disease.
    Engin A
    Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nrf2 deletion causes "benign" simple steatosis to develop into nonalcoholic steatohepatitis in mice fed a high-fat diet.
    Wang C; Cui Y; Li C; Zhang Y; Xu S; Li X; Li H; Zhang X
    Lipids Health Dis; 2013 Nov; 12():165. PubMed ID: 24188280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of farnesoid X receptor in hepatic steatosis in nonalcoholic fatty liver disease.
    Xi Y; Li H
    Biomed Pharmacother; 2020 Jan; 121():109609. PubMed ID: 31731192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic lipid accumulation: cause and consequence of dysregulated glucoregulatory hormones.
    Geisler CE; Renquist BJ
    J Endocrinol; 2017 Jul; 234(1):R1-R21. PubMed ID: 28428362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thioesterase Superfamily Member 2 Promotes Hepatic VLDL Secretion by Channeling Fatty Acids Into Triglyceride Biosynthesis.
    Alves-Bezerra M; Li Y; Acuña M; Ivanova AA; Corey KE; Ortlund EA; Cohen DE
    Hepatology; 2019 Aug; 70(2):496-510. PubMed ID: 30516845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silibinin Capsules improves high fat diet-induced nonalcoholic fatty liver disease in hamsters through modifying hepatic de novo lipogenesis and fatty acid oxidation.
    Cui CX; Deng JN; Yan L; Liu YY; Fan JY; Mu HN; Sun HY; Wang YH; Han JY
    J Ethnopharmacol; 2017 Aug; 208():24-35. PubMed ID: 28648927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Patomechanisms of hepatic steatosis].
    Fülöp P; Paragh G
    Orv Hetil; 2010 Feb; 151(9):323-9. PubMed ID: 20159747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-alcoholic steatohepatitis: new insights from OMICS studies.
    Martel C; Esposti DD; Bouchet A; Brenner C; Lemoine A
    Curr Pharm Biotechnol; 2012 Apr; 13(5):726-35. PubMed ID: 22122481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-alcoholic fatty liver disease.
    Smith BW; Adams LA
    Crit Rev Clin Lab Sci; 2011; 48(3):97-113. PubMed ID: 21875310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of hepassocin in the development of non-alcoholic fatty liver disease.
    Wu HT; Lu FH; Ou HY; Su YC; Hung HC; Wu JS; Yang YC; Wu CL; Chang CJ
    J Hepatol; 2013 Nov; 59(5):1065-72. PubMed ID: 23792031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P2Y2R Deficiency Ameliorates Hepatic Steatosis by Reducing Lipogenesis and Enhancing Fatty Acid β-Oxidation through AMPK and PGC-1α Induction in High-Fat Diet-Fed Mice.
    Dusabimana T; Park EJ; Je J; Jeong K; Yun SP; Kim HJ; Kim H; Park SW
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans.
    Benhamed F; Denechaud PD; Lemoine M; Robichon C; Moldes M; Bertrand-Michel J; Ratziu V; Serfaty L; Housset C; Capeau J; Girard J; Guillou H; Postic C
    J Clin Invest; 2012 Jun; 122(6):2176-94. PubMed ID: 22546860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.